Literature DB >> 11732002

Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.

M Fujioka1, Y Nakashima, O Nakashima, M Kojiro.   

Abstract

Sixty-eight cases of single hepatocellular carcinoma (HCC) with less than 3 cm of diameter were immunohistochemically examined for the expressions of alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II). In cancerous tissues, the expression rate was significantly higher for PIVKA-II (34 cases [50%]) than AFP (21 cases [31%]) (P <.05), suggesting a higher specificity of PIVKA-II to small HCC. Sixteen of the 68 cases (24%) were positive to both AFP and PIVKA-II, and in 8 of the 16 cases, AFP and PIVKA-II expressing areas within a nodule were clearly divided by a fibrous septum. According to histologic grades, PIVKA-II expression was confirmed in 2 of the 15 well-differentiated HCCs, and in the well-differentiated component of 6 of the 12 "nodule-in-nodule"-type well-differentiated HCCs. AFP expression was not found in well-differentiated HCCs, but found in 16 of the 40 moderately differentiated HCCs (40%) and in the moderately differentiated component of 3 of the 12 "nodule-in-nodule"-type well-differentiated HCCs. The positive rate in the tissues was correlated to the serum levels for both AFP and PIVKA-II. In addition, frequency of tissue-PIVKA-II expression was higher than tissue-AFP expression in the cases whose serum protein level was within the normal range. This indicates that AFP and PIVKA-II have different patterns of tissue expression and of secretion to the blood. In comparison with tissue-AFP-negative cases, tissue-AFP-positive HCCs had a larger tumor size, higher frequencies of portal vein invasion and intrahepatic metastasis, a high Ki-67 labeling index, and a lower rate of recurrence-free survival. Thus, tissue-AFP-positive HCCs are suggested to be biologically more malignant than those HCCs that are AFP-negative and PIVKA-II-positive.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732002     DOI: 10.1053/jhep.2001.29202

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  21 in total

1.  Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma.

Authors:  Fabrice Muscari; Jean-Pascal Guinard; Nassim Kamar; Jean-Marie Peron; Philippe Otal; Bertrand Suc
Journal:  World J Surg       Date:  2012-08       Impact factor: 3.352

Review 2.  Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma.

Authors:  Bérénice Charrière; Charlotte Maulat; Bertrand Suc; Fabrice Muscari
Journal:  World J Hepatol       Date:  2016-07-28

Review 3.  Guide for diagnosis and treatment of hepatocellular carcinoma.

Authors:  Magdy Hamed Attwa; Shahira Aly El-Etreby
Journal:  World J Hepatol       Date:  2015-06-28

4.  Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma.

Authors:  Dénes Görög; János Regöly-Mérei; Sándor Paku; László Kopper; Péter Nagy
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

5.  Risk factors for residual tumor after resection of hepatocellular carcinoma.

Authors:  Xiao-Hong Chen; Bo-Heng Zhang; Yin Xin; Zheng-Gang Ren; Jia Fan; Shuang-Jian Qiu; Jian Zhou
Journal:  World J Gastroenterol       Date:  2011-04-14       Impact factor: 5.742

Review 6.  Serum tumor markers for detection of hepatocellular carcinoma.

Authors:  Lin Zhou; Jia Liu; Feng Luo
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

7.  Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma < or =4 cm.

Authors:  Toshifumi Wakai; Yoshio Shirai; Takeshi Suda; Naoyuki Yokoyama; Jun Sakata; Pauldion V Cruz; Hirokazu Kawai; Yasunobu Matsuda; Masashi Watanabe; Yutaka Aoyagi; Katsuyoshi Hatakeyama
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

8.  Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma.

Authors:  Chang Liu; Guang-Qin Xiao; Lu-Nan Yan; Bo Li; Li Jiang; Tian-Fu Wen; Wen-Tao Wang; Ming-Qing Xu; Jia-Yin Yang
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

9.  Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization.

Authors:  Jun Xiao; Guojian Li; Shuhan Lin; Ke He; Hao Lai; Xianwei Mo; Jiansi Chen; Yuan Lin
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

10.  Stereotactic Body Radiation Therapy: A New Strategy for Loco-Regional Treatment for Hepatocellular Carcinoma While Awaiting Liver Transplantation.

Authors:  Tadahiro Uemura; Alexander Kirichenko; Mark Bunker; Molly Vincent; Lorenzo Machado; Ngoc Thai
Journal:  World J Surg       Date:  2019-03       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.